

# Perimeter Medical Imaging AI Announces its Participation in Multiple Upcoming Industry Conferences and Events

TORONTO--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced today that it will participate in the following upcoming industry events and conferences:

- Dr. Anthony Lucci from the Department of Breast Surgical Oncology, Division of Surgery at MD Anderson Cancer Center will present on Optical Coherence Tomography at Mayo Clinic's CME course entitled "[Breast Cancer Care: Innovation, Disruptive Technologies and Early Adopters](#)" on September 17, 2021 in Rochester, MN. Perimeter is a sponsor in the exhibit hall.
- Perimeter's poster entitled "Wide-Field OCT Imaging May Reduce Economic Impact on Pathology of Routine Cavity Margins in Lumpectomy Surgeries" is being presented at [CAP21](#)(Annual Meeting of the College of American Pathologists) taking place September 25-28, 2021 in Chicago, IL.
- Perimeter is hosting a (virtual) industry event with the American Society of Breast Surgeons (ASBrS) entitled "Is OCT the Next Game Changer in Margin Visualization?". Three surgeons from prestigious institutions involved in Perimeter's clinical trials will present multiple patient cases in a Webinar taking place at 7 pm ET on October 5, 2021. [Learn more](#) and [register here](#).
- Perimeter will participate in the [TME KOL Summit 2.0 Symposium Roundtable](#) in Las Vegas, NV on November 5-6, 2021.
- Perimeter will participate in the virtual [SSO Fellows Institute 2021](#), which sponsored by the Society of Surgical Oncology and American Society of Breast Surgeons, on November 11, 2021.

Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "Our commercial team is actively showcasing our innovative Perimeter S-Series OCT at multiple, targeted industry events over the coming months. We are grateful for the support of many leading surgeons and key opinion leaders who are sharing their clinical experiences using our imaging technology in the OR for 'real-time' visualization of excised tissue and shaved margins."

## About Perimeter S-Series OCT

Cleared by the U.S. FDA, Perimeter S-Series Optical Coherence Tomography (OCT) is a novel medical imaging system that provides clinicians with cross-sectional, real-time margin visualization (1-2 mm below the surface) of an excised tissue specimen. Giving physicians the ability to visualize microscopic tissue structures "real time" in the operating room has the potential to result in better long-term outcomes for patients and lower costs to the healthcare

system.

## **About Perimeter B-Series OCT with ImgAssist AI**

Perimeter is advancing the development of its proprietary, next-gen “ImgAssist” artificial intelligence technology under its ATLAS AI project, which is made possible, in part, by a US\$7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter has plans to initiate a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery.

## **About Perimeter Medical Imaging AI, Inc.**

With headquarters in Toronto, Canada and Dallas, Texas, [Perimeter Medical Imaging AI](#) (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company’s ticker symbol “PINK” is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company’s dedication to helping surgeons, radiologists, and pathologists use Perimeter’s imaging technology and AI in the fight against breast cancer, which is estimated to [account for 30%](#) of all female cancer diagnoses this year.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

## **Forward-Looking Statements**

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results, and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the industry events the Company plans to attend, the potential benefits of Perimeter’s S-Series OCT, and the Company’s plans for development of its B-Series OCT is forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social

uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2020 which is available on Perimeter's SEDAR profile at [www.sedar.com](http://www.sedar.com), and could cause actual events or results to differ materially from those projected in any forward-looking statements. In particular, we note the risk that our technology may not achieve the anticipated benefits in terms of surgical outcomes. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210917005120/en/>

Shushu Feng  
Perimeter Medical Imaging AI, Inc.  
Main: 214-845-5154  
Toll-free: 888-988-7465 (PINK)  
[media@perimetermed.com](mailto:media@perimetermed.com)

Ben Shamsian or Joe Dorame  
Lytham Partners, LLC  
Direct: 646-829-9701  
Main: 602-889-9700  
[PINK@lythampartners.com](mailto:PINK@lythampartners.com)

Source: Perimeter Medical Imaging AI, Inc.